CRNX
HealthcareCrinetics Pharmaceuticals, Inc. · Biotechnology · $4B
What is Crinetics Pharmaceuticals, Inc.?
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on rare endocrine diseases and endocrine-related tumors. Headquartered in San Diego, California, the company is building a pipeline of oral, nonpeptide therapies targeting conditions with limited treatment options.
Crinetics discovers and develops small-molecule drugs designed to act on specific hormone receptors. Its lead candidate, paltusotine, is an oral somatostatin receptor agonist that has completed Phase III trials for acromegaly and Phase II trials for carcinoid syndrome and nonfunctional neuroendocrine tumors. Additional pipeline candidates target congenital hyperinsulinism, Cushing's disease, and congenital adrenal hyperplasia — all rare conditions where patients have historically had few oral treatment choices.
Crinetics was incorporated in 2008 and is headquartered in San Diego, California.
- Paltusotine — oral therapy for acromegaly and neuroendocrine tumors
- CRN04777 — oral candidate for congenital hyperinsulinism (Phase I)
- CRN04894 — oral candidate for Cushing's disease and congenital adrenal hyperplasia (Phase I)
- Rare endocrine disease drug discovery platform
Is CRNX a Good Stock to Buy?
UQS Score rates CRNX as Poor overall, reflecting the realities of a pre-revenue clinical-stage company.
The Growth and Risk pillars stand out as relative bright spots. The pipeline's late-stage clinical progress — particularly paltusotine's Phase III completion — represents meaningful advancement, and the company's risk profile is considered manageable for a development-stage biotech.
Quality and Moat are both rated Weak, which is typical for companies without commercial revenue or established market position. Valuation is rated Elevated, suggesting the market has already priced in considerable pipeline optimism.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CRNX pay dividends?
No — Crinetics Pharmaceuticals, Inc. does not currently pay a dividend.
CRNX does not pay a dividend. As a clinical-stage company, Crinetics directs available capital toward research, clinical trials, and pipeline development rather than shareholder distributions. This is standard practice for pre-revenue biotechs, where reinvestment in the drug pipeline is the primary path to long-term value creation.
When does CRNX report earnings?
Crinetics Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline milestones rather than product revenue. Investors typically watch for updates on regulatory submissions, trial readouts, and partnership activity.
For the most recent quarter's results and pipeline updates, visit Crinetics Pharmaceuticals' investor relations page directly.
CRNX Price History
+121.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Crinetics Pharmaceuticals, Inc.?
Based on Crinetics Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CRNX Long-term Outlook
The UQS Growth pillar is rated Good, reflecting the pipeline's late-stage progress and the potential commercial opportunity in rare endocrine diseases. However, the Elevated Valuation pillar signals that much of this optimism may already be reflected in the current share price. The Risk pillar is rated Good, suggesting the company's financial and operational risk is not considered extreme relative to clinical-stage peers — though binary trial and regulatory outcomes remain inherent to the biotech model.
Growth drivers
- Potential regulatory approval and commercialization of paltusotine for acromegaly
- Expansion of pipeline candidates into additional rare endocrine indications
- Growing unmet need in rare disease markets with limited oral treatment options
Key risks
- Clinical or regulatory setbacks for any pipeline candidate could significantly impact the company
- Elevated valuation leaves limited margin of safety if pipeline milestones are delayed
- Pre-revenue status means ongoing dependence on capital markets for funding
CRNX vs Peers
Crinetics operates in a competitive rare-disease and specialty biotech landscape alongside several development-stage peers.
Spyre focuses on immunology and inflammatory diseases, pursuing a different therapeutic area than Crinetics' endocrine-disease specialization.
Viking targets metabolic and endocrine disorders including obesity and NASH, overlapping broadly with the hormone-related disease space.
Amicus concentrates on rare genetic and lysosomal storage diseases, sharing the rare-disease commercial model but with a distinct therapeutic focus.
Frequently Asked Questions
What does Crinetics Pharmaceuticals do?
Crinetics Pharmaceuticals is a clinical-stage company that discovers and develops oral, nonpeptide drugs for rare endocrine diseases and endocrine-related tumors. Its pipeline targets conditions such as acromegaly, carcinoid syndrome, congenital hyperinsulinism, and Cushing's disease — areas where patients historically have had limited oral treatment options.
Does CRNX pay dividends?
No, CRNX does not currently pay a dividend. As a pre-revenue, clinical-stage biopharmaceutical company, Crinetics reinvests available capital into research and clinical development. Dividend payments are not typical for companies at this stage of development.
When does CRNX report earnings?
Crinetics reports financial results quarterly, in line with standard US public company requirements. Because it is pre-revenue, reports focus on pipeline progress and cash position rather than product sales. Check Crinetics' investor relations page for the most current reporting schedule.
Is CRNX a good stock to buy?
UQS Score rates CRNX as Poor overall, driven by Weak Quality and Moat scores typical of pre-revenue biotechs, alongside an Elevated Valuation. The Growth and Risk pillars are rated Good, reflecting pipeline progress. Whether CRNX fits your portfolio depends on your risk tolerance and investment horizon — view the full breakdown on UQS Pro.
Is CRNX overvalued?
The UQS Valuation pillar for CRNX is rated Elevated, suggesting the current market price reflects considerable pipeline optimism. For clinical-stage biotechs, valuation is heavily driven by probability-weighted expectations of regulatory success, which introduces meaningful uncertainty.
How does CRNX compare to its competitors?
CRNX competes in the rare-disease biotech space alongside companies like Viking Therapeutics, Spyre Therapeutics, and Amicus Therapeutics. Crinetics differentiates itself through its focus on oral, nonpeptide endocrine therapies — a relatively narrow and specialized niche. UQS Pro provides side-by-side pillar comparisons across these peers.
What is CRNX's market cap bracket?
CRNX is classified as a mid-cap stock. This places it in a range that is larger than most early-stage biotechs but below the large-cap threshold — reflecting the market's recognition of its late-stage pipeline while acknowledging it has not yet reached commercial scale.
Who founded Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals was incorporated in 2008 and is headquartered in San Diego, California. For detailed founding history and leadership background, the company's official website and SEC filings provide publicly available information.
Is CRNX a long-term quality investment?
From a long-term quality perspective, CRNX currently scores Poor on the UQS composite, with Weak Quality and Moat pillars. However, the Good Growth rating reflects meaningful pipeline advancement. Long-term quality potential depends heavily on whether paltusotine and subsequent candidates achieve regulatory approval and commercial traction.
What is the main competitive advantage of Crinetics Pharmaceuticals?
Crinetics' differentiation lies in its focus on oral, nonpeptide somatostatin receptor agonists — a drug class that could offer patients a more convenient alternative to injectable therapies. Targeting rare endocrine diseases also provides potential for orphan drug designations and less crowded competitive landscapes.
What sector does CRNX belong to?
CRNX belongs to the Healthcare sector, specifically within the biopharmaceutical and rare-disease drug development space. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to compare quality profiles across the sector.
Unlock Full CRNX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare CRNX side-by-side with rare-disease peers
- ✓Track pipeline risk and valuation signals over time
- ✓Get the complete analyst-style quality breakdown
Pro Analysis
CRNX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 30.8 | 0.4 | 20.0 | 72.8 | 74.2 | 0.0 | +0.1 |
| May 10, 2026 | 30.7 | 0.0 | 20.0 | 72.8 | 74.2 | 0.0 | 0.0 |
| May 7, 2026 | 30.7 | 0.0 | 20.0 | 72.8 | 74.1 | 0.0 | 0.0 |
| Apr 2, 2026 | 30.7 | 0.0 | 20.0 | 72.8 | 74.3 | 0.0 | — |
CRNX — Pillar Breakdown
Quality
— 0.4/100 (25%)Crinetics Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 72.8/100 (20%)Crinetics Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.2/100 (15%)Crinetics Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Crinetics Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 20/100 (25%)Crinetics Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CRNX.
Score Composition
Financial Data
More Stock Analysis
How is the CRNX UQS Score Calculated?
The UQS (Unified Quality Score) for Crinetics Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Crinetics Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Crinetics Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.